miR-128 was fully functional in NSCLC tumorigenesis, partly by modulating lymphangiogenesis and revascularization by targeting VEGF-C and could simultaneously inhibit ERK, AKT, and p38 signaling pathways. The gene discussed is MAPK1; the disease is non-small cell lung carcinoma.